Biotechnology
Clinical-stage biotech; commercial-stage biotech; platform biotech; biologics; cell/gene therapy.
NTM Growth %
to
EV / NTM Rev (x)
to
Mkt Cap ($B)
to
Showing 1 of 1 companies
| Company | Mkt Cap ↓ | EV | EV / LTM Rev | EV / NTM Rev | EV / LTM EBITDA | EV / NTM EBITDA | NTM Growth | Gross Margin | EBITDA Margin | FCF Margin | Rule of 40 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 2.1x | 1.9x | 9.1x | 7.2x | 9.5% | 37.2% | 21.8% | 10.6% | 20.1% | |||
| Mean | 2.1x | 1.9x | 9.1x | 7.2x | 9.5% | 37.2% | 21.8% | 10.6% | 20.1% | |||
| GRFSGrifols, S.A. | $6.85B | $14.84B | 2.1x | 1.9x | 9.1x | 7.2x | 9.5% | 37.2% | 21.8% | 10.6% | 20.1% |